Skip to main content

Table 2 Cox-regression analysis of risk factors

From: How to manage synchronous endometrial and ovarian cancer patients?

Variables Overall survival Recurrence-free survival
N (event) HR (95% CI) P-value N (event) HR (95% CI) P-value
Age 47 (4) 1.05 (0.93–1.18) 0.428 47 (12) 1.05 (0.98–1.11) 0.173
Pelvic_LN_pathology
 No 41 (3) 1   41 (9) 1  
 Yes 6 (1) 3.57 (0.36–35.05) 0.275 6 (3) 3.86 (0.96–15.46) 0.057
paraaortic_LN
 No 42 (3) 1   42 (9) 1  
 Yes 5 (1) 3.80 (0.39–36.90) 0.250 5 (3) 4.84 (1.21–19.41) 0.026
LVS
 No 40 (3) 1   40 (11) 1  
 Yes 7 (1) 2.29 (0.24–22.13) 0.474 7 (1) 0.54 (0.07–4.18) 0.554
Endocervix-invasion
 No 42 (4) 1   42 (11) 1  
 Yes 5 (0)    5 (1) 0.60 (0.08–4.64) 0.623
Pelvic peritoneum invasion
 No 36 (2) 1   36 (8) 1  
 Yes 11 (2) 3.17 (0.44–22.96) 0.253 11 (4) 1.63 (0.49–5.41) 0.427
Stage_EM
 1 + 2 32 (2) 1   32 (9) 1  
 3 + 4 15 (2) 2.60 (0.36–18.54) 0.342 15 (3) 0.71 (0.19–2.63) 0.610
Stage_OV
 1 + 2 27 (0) 1   27 (3) 1  
 3 + 4 8 (2)    8 (6) 12.16 (2.87–51.59) 0.001
Histology_EM
 Non-endometrioid 11 (3) 1   11 (7) 1  
 Endometrioid 36 (1) 0.09 (0.01–0.84) 0.035 36 (5) 0.15 (0.05–0.49) 0.002
Histology_OV
 Non-endometrioid 22 (4) 1   22 (9) 1  
 Endometrioid 25 (0)    25 (3) 0.20 (0.05–0.73) 0.016
Grade_EM
 1 17 (1) 1   17 (3) 1  
 2 + 3 22 (1) 0.81 (0.05–13.01) 0.884 22 (2) 0.59 (0.1–3.55) 0.567
Grade_OV
 1 15 (1) 1   15 (4) 1  
 2 + 3 25 (2) 1.22 (0.11–13.45) 0.873 25 (5) 0.84 (0.23–3.14) 0.798
Adjuvant CTx
 No 7 (1) 1   7 (1) 1  
 Yes 40 (3) 0.47 (0.05–4.54) 0.516 40 (11) 1.95 (0.25–15.16) 0.521
Adjuvant RTx
 No 42 (4) 1   42 (10) 1  
 Yes 5 (0)    5 (2) 1.35 (0.30–6.17) 0.700
  1. CI Confidence interval, CTx Chemotherapy, RTx Radiotherapy, EM Endometrium, OV Ovary, HR Hazard ratio, LN Lymph nodes